Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Major study shows aspirin can cut polyp return in GI cancer patients

06.03.2003


Patients who have had colorectal cancer may reduce their risk of suffering a recurrence by taking an aspirin daily, according to a new study conducted by a University of North Carolina at Chapel Hill physician and colleagues around the United States.



The study showed that subjects who took 325 milligrams of aspirin each day had a 35 percent lower risk of developing polyps in their colons during the period examined than did patients who received an inactive placebo. Polyps are considered precursors to most colorectal cancers. A report on the findings appears in the March 6 issue of the New England Journal of Medicine. More than 100 medical centers and clinics throughout the United States participated in the study.

"From both animal research and observational studies, we’ve recognized for a long time that aspirin might decrease the risk of colon cancer," said Dr. Robert S. Sandler, the study’s principal investigator. "To find out whether aspirin really worked, we needed a randomized trial where we could compare aspirin with a placebo. With the help of a large consortium of hospitals and a large number of patients, that’s what we’ve done. "


Sandler, professor of medicine and epidemiology at the UNC schools of medicine and public health, also is chief of the division of digestive diseases and nutrition and director of UNC’s Center for Gastrointestinal Biology and Disease.

The double-blind study involved randomly assigning half of the 635 patients who previously suffered colorectal cancer to an aspirin treatment group and the other half to the placebo group, he said. He and colleagues gathered data, determined the percentage of patients with recurrent polyps and, after adjusting for age, sex, cancer stage and the timing of colonoscopies, analyzed how patients fared in relation to which of the two groups they were in.

Doctors found that among the 517 patients who had at least one colonoscopy over the previous year or so, 17 percent of those in the treatment group had one or more polyps compared to 27 percent of those in the other group.

"Also, we found that the average number of polyps was lower in the aspirin group, and aspirin delayed the appearance of polyps and slowed their development," Sander said. "The fact that each of these measures went in the same direction supports the idea that this is a real effect, and it’s not simply coincidence."

For ethical reasons, and so that doctors and patients could learn about the findings sooner, an independent data and safety monitoring board ended the study early when it found statistically significant differences in the recurrence of polyps during an interim analysis.

"These findings are good news and encouraging, but they don’t mean that people can assume they can protect themselves completely from colon cancer," the UNC physician said. "We view aspirin or drugs like aspirin as being an adjunct to colonoscopy, during which we can remove any polyps that aspirin failed to prevent."

Patients in the new study already had had cancer, and the risk of colon cancer in an average person would be lower, Sandler said. As a result, the protective effect of aspirin might be lower in other people as well. Somewhat fewer than 5 percent of polyps become cancerous, and individuals who have had one or more of the unhealthy growths are about three times more likely to develop a colon cancer than those who have had none.

"One good thing about these results is that they demonstrate you can change the natural history of polyps by intervening," he said. "Eventually, we might be able to find other chemicals, nutrients or vitamins that we could use that would do the same thing."

Sandler was a co-author of a related investigation appearing in the same issue of the journal that showed a similar protective effect of aspirin, although at a lower dose comparable to baby aspirin. The 1,084 patients in that study had polyps previously diagnosed but not colorectal cancer. Dr. John A. Baron of Dartmouth Medical School was principal investigator for that research.

In an article accompanying the two studies, Dr. Thomas F. Imperiale of Indiana University said determining whether aspirin has a role in preventing colon cancer must await the results of studies of whether it can be used to decrease screening or surveillance.

"Although aspirin may be of some benefit in preventing colorectal cancer, it cannot yet be recommended for this indication and is not a substitute for screening and surveillance," Imperiale wrote. "Nevertheless, the(se) well-conducted trials … provide proof of the principle that aspirin moderately reduces the risk of recurrent colorectal neoplasia and provide support for the assumptions and probabilities that have been used in published analyses of cost effectiveness."

An earlier study suggested that calcium can prevent polyp formation to about the same extent that aspirin can, Sandler said. Before people begin taking aspirin, they should discuss the matter with their doctors.

"We recommend that people over age 50 undergo screening for colon cancer," he said. "If they are screened with colonoscopy, and it is normal, they do not need the exam again for 10 years. There are other screening tests that are also effective, including fecal occult blood testing every year and sigmoidoscopy, which views half as much of the colon, every five years."


Co-authors of the first report are Dr. Susan Halabi and Susan Budinger of Duke University Medical Center, Baron and Dr. J. Marc Pipas of Dartmouth, Dr. Electra Paskett of Wake Forest University School of Medicine, Dr. Roger Keresztes of Weill Medical College of Cornell University and Dr. Nicholas Petrelli of Roswell Park Cancer Institute in Buffalo. Others are Drs. Daniel D. Karp of the Eastern Cooperative Oncology Group, Charles L. Loprinzi of the Mayo Clinic, Gideon Steinbach of M.D. Anderson Cancer Center in Houston and Richard Schilsky of the University of Chicago.

The National Cancer Institute supported both studies.

Note: Sandler can be reached at (919) 966-0090 or via e-mail at rsandler@med.unc.edu. Copies of his paper are available to reporters who call David Williamson at (919) 962-8596.

News Services contact: David Williamson (919) 962-8596

David Williamson | EurekAlert!
Further information:
http://www.unc.edu/

More articles from Health and Medicine:

nachricht Investigators may unlock mystery of how staph cells dodge the body's immune system
22.09.2017 | Cedars-Sinai Medical Center

nachricht Monitoring the heart's mitochondria to predict cardiac arrest?
21.09.2017 | Boston Children's Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Rainbow colors reveal cell history: Uncovering β-cell heterogeneity

22.09.2017 | Life Sciences

Penn first in world to treat patient with new radiation technology

22.09.2017 | Medical Engineering

Calculating quietness

22.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>